Free Trial

Inhibikase Therapeutics (IKT) Institutional Ownership

Inhibikase Therapeutics logo
$1.85 -0.13 (-6.57%)
(As of 11:20 AM ET)

Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)

Current
Institutional Ownership
Percentage
3.81%
Number of
Institutional Buyers
(last 12 months)
1
Total
Institutional Inflows
(last 12 months)
$713.39K
Number of
Institutional Sellers
(last 12 months)
0
Get IKT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

IKT Institutional Buying and Selling by Quarter

Inhibikase Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024 Armistice Capital LLC589,575$713K0.0%N/A8.170%
11/15/2023 Armistice Capital LLC186,046$259K0.0%-62.5%3.477%
9/21/2023 Barclays PLC11,455$41K0.0%N/A0.214%
8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266%
5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286%
2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817%
7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259%
5/6/2022 Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461%
5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476%
5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657%
5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486%
2/14/2022 Murchinson Ltd.220,947$327K0.0%-31.2%0.878%
2/8/2022 Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586%
2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279%
11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019%
11/16/2021 Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103%
11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202%
8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926%
8/16/2021 Antara Capital LP250,000$700K0.0%N/A2.467%
8/16/2021 Warberg Asset Management LLC90,000$252K0.0%N/A0.888%
8/16/2021 Sabby Management LLC421,200$1.18M0.2%N/A4.157%
8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083%
8/13/2021 Murchinson Ltd.320,947$899K0.3%N/A3.167%
8/13/2021 Vanguard Group Inc.470,615$1.32M0.0%N/A4.644%
8/13/2021 FMR LLC433,300$1.21M0.0%+333.3%4.276%
8/12/2021 Kepos Capital LP700,000$1.96M0.1%N/A6.908%
5/21/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178%
5/18/2021 Millennium Management LLC11,224$67K0.0%N/A0.112%
5/18/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178%
5/17/2021 HRT Financial LP11,614$69K0.0%N/A0.115%
(Data available from 1/1/2016 forward)

IKT Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of IKT shares?

During the previous two years, the following institutional investors and hedge funds held shares of Inhibikase Therapeutics shares: Armistice Capital LLC ($713K), Blair William & Co. IL ($114K), and Hamilton Lane Advisors LLC ($50K), Barclays PLC ($41K).Learn more on IKT's institutional investors.

What percentage of Inhibikase Therapeutics stock is owned by institutional investors?

3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings.

Which institutional investors have been buying Inhibikase Therapeutics stock?

The following institutional investors have purchased Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($589.58K), Hamilton Lane Advisors LLC ($82.82K), Blair William & Co. IL ($50K), and Barclays PLC ($11.46K).

How much institutional buying is happening at Inhibikase Therapeutics?

Institutional investors have bought a total of 733,847 shares in the last 24 months. This purchase volume represents approximately $1.44M in transactions.

Which Inhibikase Therapeutics major shareholders have been selling company stock?

The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), and Hamilton Lane Advisors LLC ($69.02K).

How much institutional selling is happening at Inhibikase Therapeutics?

Institutional investors have sold a total of 379,516 shares in the last 24 months. This volume of shares sold represents approximately $1.93M in transactions.



This page (NYSE:IKT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners